摘要
目的 探讨舍曲林联合喹硫平治疗难治性抑郁症的临床疗效和安全性.方法 将58例难治性抑郁症患者随机分为两组,每组29例.两组均口服舍曲林治疗,在此基础上研究组联合喹硫平治疗,观察12周.于治疗前及治疗1周、2周、4周、6周、12周末采用汉密顿抑郁量表及汉密顿焦虑量表评定临床疗效,副反应量表评定不良反应.结果 治疗后两组汉密顿抑郁量表及汉密顿焦虑量表评分均较治疗前有显著性下降（P＜0.01）,同期研究组均较对照组下降显著（P＜0.05或0.01）;治疗12周末,研究组有效率65.5%,对照组为37.9%,研究组显著高于对照组（χ2=4.419,P＜0.05）.研究组不良反应发生率为41.4%,对照组为34.5%,两组不良反应程度均较轻,同期副反应量表评分差异无显著性（P＞0.05）.结论喹硫平对治疗难治性抑郁症具有增效作用;舍曲林联合喹硫平治疗难治性抑郁症疗效显著,起效快,安全性高,依从性好,显著优于单用舍曲林治疗.
Objective To explore the clinical efficacy and safety of sertraline combined with quetiapine in the treatment of treatment-resistant depression （TRD）. Methods Fifty-eight TRD patients were randomly divided into two groups of 29 ones each, both groups took orally sertraline, and reseach group was plus quetiapine for 12 weeks. Clinical efficacies were assessed with the Hamilton Depression Scale （HAMD） and Hamilton Anxiety Scale （HAMA） before treatment and at the end of the 1st, 2nd, 4th, 6th and 12th week, and adverse reactions with the Treatment Emergent Symptom Scale （TESS）. Results The HAMD and HAMA scores of both groups lowered more significantly after treatment compared with pretreatment（P〈0.01）, so did in the research than in the control group in the correspondting period（P〈0.05 or 0.0J） ; at the end of the 12th week, effective rates were respectively 65.5% in the research and 37. 9% in the control group, the former was significantly higher than the latter （x2 = 4. 419,P〈0.05）. The incidences of adverse reactions were respectively 41.4% in the research and 34.5% in the control group, adverse reactions of both groups were mild, and there were no significant differences in the TESS scores in the correspondting period（P〉0.05）. Conclusion Quetiapine has a synergistic ac- tion on treatment-resistant depression; the combination of setraline with quetipine has notable curative effect, takes effect more rapidly, has higher safety and better compliance comapred with single setraline treatment.
出处
《临床心身疾病杂志》
CAS
2011年第4期313-314,320,共3页
Journal of Clinical Psychosomatic Diseases
